160 related articles for article (PubMed ID: 35117169)
1. Neoadjuvant systemic therapy does not compromise local control after breast-conserving surgery: a single-center, propensity score matching study in China.
Yang F; Wu SY; Mo M; Xiao Q; Yang X; Liu YY; Li JW; Shao ZM; Liu GY
Transl Cancer Res; 2020 Jan; 9(1):155-165. PubMed ID: 35117169
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
Choi YJ; Shin YD; Song YJ
World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
[TBL] [Abstract][Full Text] [Related]
3. Is repeat breast conservation possible for small ipsilateral breast cancer recurrence?
Li Y; Li WW; Yuan L; Xu B
Cancer; 2022 Nov; 128(22):3919-3928. PubMed ID: 36128621
[TBL] [Abstract][Full Text] [Related]
4. Long-term Survival Comparison of Repeated Breast-conserving Surgery Versus Mastectomy for Patients with DCIS with Ipsilateral Breast Tumor Recurrence: A Real-world Longitudinal Study.
Li Q; Wang K; Yang L; Wu Q; Zhu W; Li Z; Shi Y; Zhang X; Li H
Clin Breast Cancer; 2021 Aug; 21(4):360-372. PubMed ID: 33846099
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.
Kuo SH; Lo C; Chen YH; Lien HC; Kuo WH; Wang MY; Lee YH; Huang CS
Clin Breast Cancer; 2018 Dec; 18(6):441-450.e2. PubMed ID: 29709458
[TBL] [Abstract][Full Text] [Related]
6. Comparison of long-term oncological outcomes after central lumpectomy versus nipple-sparing breast-conserving surgery for centrally located breast cancer: a propensity score-matched study.
Hwang YH; Yoo TK; Lee SB; Kim J; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH
Breast Cancer Res Treat; 2024 May; 205(1):117-125. PubMed ID: 38332198
[TBL] [Abstract][Full Text] [Related]
7. Impact of Trastuzumab on Ipsilateral Breast Tumor Recurrence for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer after Breast-Conserving Surgery.
Cheun JH; Won J; Jung JG; Kim HK; Han W; Lee HB
J Breast Cancer; 2021 Jun; 24(3):301-314. PubMed ID: 34190441
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience of patients with ductal carcinoma in situ of the breast treated with breast-conserving surgery plus radiotherapy: a preliminary report.
Jang JY; Ryu MR; Kim SW; Kay CS; Kim YS; Oh YK; Kwon HC; Yoon SC; Park WC; Song BJ; Oh SJ; Jung SS; Won JM; Kim SN; Chung SM
Cancer Res Treat; 2005 Dec; 37(6):344-8. PubMed ID: 19956370
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ.
Xu FF; Zheng SF; Xu C; Cai G; Wang SB; Qi WX; Wang CF; Chen JY; Lu C
Oncoimmunology; 2021 Mar; 10(1):1875637. PubMed ID: 33796401
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival outcomes of repeat lumpectomy for ipsilateral breast tumor recurrence: a propensity score-matched analysis.
Baek SY; Kim J; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn SH; Lee SB
Breast Cancer Res Treat; 2021 Jan; 185(1):155-164. PubMed ID: 32935236
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics and prognosis of patients with ipsilateral breast tumor recurrence after breast conservation therapy].
Sun GY; Wang SL; Tang Y; Jin J; Song YW; Liu YP; Wang WH; Fang H; Chen SY; Ren H; Liu XF; Yu ZH; Li YX
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):352-358. PubMed ID: 29860762
[No Abstract] [Full Text] [Related]
12. Comparison of Long-Term Oncological Outcomes in Oncoplastic Breast Surgery and Conventional Breast-Conserving Surgery for Breast Cancer: A Propensity Score-Matched Analysis.
Oh MY; Kim Y; Kim J; Cheun JH; Jung JG; Kim HK; Lee HB; Han W
J Breast Cancer; 2021 Dec; 24(6):520-530. PubMed ID: 34979598
[TBL] [Abstract][Full Text] [Related]
13. Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic Index.
Ishitobi M; Ohsumi S; Inaji H; Ohno S; Shigematsu H; Akiyama F; Iwase T; Akashi-Tanaka S; Sato N; Takahashi K; Oura S
Cancer; 2012 Sep; 118(18):4385-93. PubMed ID: 22252882
[TBL] [Abstract][Full Text] [Related]
14. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.
Shurell E; Olcese C; Patil S; McCormick B; Van Zee KJ; Pilewskie ML
Cancer; 2018 Jan; 124(1):46-54. PubMed ID: 28960259
[TBL] [Abstract][Full Text] [Related]
15. Surgical management of ipsilateral breast tumor recurrence.
Kolben T; Schwarz TM; Goess C; Blume C; Degenhardt T; Engel J; Wuerstlein R; Ditsch N; Harbeck N; Kahlert S
Int J Surg; 2015 Nov; 23(Pt A):141-6. PubMed ID: 26449651
[TBL] [Abstract][Full Text] [Related]
16. Margin width and local recurrence after breast conserving surgery for ductal carcinoma in situ.
Ekatah GE; Turnbull AK; Arthur LM; Thomas J; Dodds C; Dixon JM
Eur J Surg Oncol; 2017 Nov; 43(11):2029-2035. PubMed ID: 28917445
[TBL] [Abstract][Full Text] [Related]
17. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
Kim HJ; Han W; Yi OV; Shin HC; Ahn SK; Koh BS; Moon HG; You JH; Son BH; Ahn SH; Noh DY
Breast Cancer Res Treat; 2011 Nov; 130(2):499-505. PubMed ID: 21853352
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
Vrieling C; van Werkhoven E; Maingon P; Poortmans P; Weltens C; Fourquet A; Schinagl D; Oei B; Rodenhuis CC; Horiot JC; Struikmans H; Van Limbergen E; Kirova Y; Elkhuizen P; Bongartz R; Miralbell R; Morgan DA; Dubois JB; Remouchamps V; Mirimanoff RO; Hart G; Collette S; Collette L; Bartelink H;
JAMA Oncol; 2017 Jan; 3(1):42-48. PubMed ID: 27607734
[TBL] [Abstract][Full Text] [Related]
19. Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates.
Gentilini O; Botteri E; Veronesi P; Sangalli C; Del Castillo A; Ballardini B; Galimberti V; Rietjens M; Colleoni M; Luini A; Veronesi U
Ann Surg Oncol; 2012 Nov; 19(12):3771-6. PubMed ID: 22618719
[TBL] [Abstract][Full Text] [Related]
20. HER2 overexpression in ductal carcinoma in situ is associated with ipsilateral breast cancer recurrence after conservative surgery.
Gong DH; Ge JY; Chen YY; Ding KF; Yu KD
Transl Cancer Res; 2020 Jun; 9(6):3787-3793. PubMed ID: 35117746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
